ClinicalTrials.gg
WithdrawnNCT06213298Updated Oct 16, 2026

Effect of Kava on Anxiety and Stress in Cancer Survivors

An Early Phase 1 interventional study of Kava and Placebo in Kava, Anxiety and Stress, sponsored by Masonic Cancer Center, University of Minnesota. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Primary conditionNeoplasmsRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasms
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Masonic Cancer Center, University of Minnesota · Early Phase 1, Interventional, and Supportive care

How we know

Why this study was withdrawn
Funding unavailable
Updated Oct 16, 2026Now WithdrawnNow Terminated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a pilot, two-arm, randomized, blinded, placebo-controlled cross-over clinical trial to study the safety and effect of 14 days of kava on anxiety and physiologic stress in survivors of cancer and its treatment. Participants will be randomized to take either kava first or placebo first. Kava 75 mg or placebo will be taken three time daily (TID) for 14 days (Period 1), followed by a washout period of 14-28 days. Thereafter, the participant will take either placebo or kava TID for 14 days (Period 2), whichever he/she did not take in Period 1.

02

Conditions studied

  • Kava
  • Anxiety
  • Stress
  • Cancer
  • Depression
  • Sleep

Browse trials for

03

In context

Neoplasms Reclassified

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

Browse Neoplasms studies →

Lead sponsor

Masonic Cancer Center, University of Minnesota is the lead sponsor of 286 studies on the registry; 35 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 28 (72%) have results posted.

Compared within Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed curative-intent treatment for breast, gynecologic, lung, or head/neck cancer within the last 24 months without clinical and/or radiographic evidence of recurrence at the time of the last follow up
  • Score of ≥ 5 on the GAD-7 questionnaire, considered to be mild anxiety
  • performance status 0-1
  • Normal kidney and liver function within 28 days prior to the first dose of kava or placebo
  • Willing to abstain from benzodiazepine and alcohol use during the kava or placebo intervention and for at least 14 days after completion
  • Ability to provide written,

Exclusion criteria

Exclusion Criteria:

  • Regular use of benzodiazepines, defined as ≥ 2 times weekly, within 14 days prior to study registration
  • Anti-cancer therapy within 28 days prior to registration, and/or during study participation, except for aromatase inhibitors
  • Known liver disease such as cirrhosis (any class), active infectious hepatitis, immune-mediated hepatitis, hemochromatosis, non-alcoholic steatohepatitis (NASH), or Wilson's disease
  • Use of acetaminophen at doses more than 2000 mg daily for more than three days per week within 7 days prior to the first dose of kava or placebo intervention
  • Chronic use of high-intensity statin therapy
  • Significant uncontrolled conditions or situations, which in the judgment of the enrolling investigator, could affect safety and/or ability to adhere to study requirements
  • Adjustments in anti-depressants and/or anxiolytic medications within 8 weeks prior to study registration
  • Known allergy to kava
  • Women who are pregnant, intend to become pregnant, or are nursing
  • Regular use of alcohol, defined as ≥ 3 times per week, regardless of amount, within 14 days prior to study registration
  • Parkinson's disease
  • History of or current substance use disorder by self-report
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Early Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Kava

    75mg of Kava taken three times daily for 14 days. Participants will then enter into a washout period of 14-28 days.

    Drug: Kava

  • Placebo comparator
    Placebo

    The placebo will be taken three times daily for 14 days. Participants will then enter into a washout period of 14-28 days.

    Dietary Supplement: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in PROMIS anxiety measure score after 14 days of kava or placebo

    PROMIS- 29 questionnaire will be administered to determine anxiety level. Scale 4-20. Higher score indicates higher anxiety.

    Time frame: 14 days

  2. Incidence of adverse events attributable to kava

    Assessed using CTCAE v5.0

    Time frame: 14 days

07

Study locations

1 site
  • Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
08

References and documents

Individual participant data

Plan to share: No — De-identified data will be shared amongst the study team via Box.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2024 to primary completion in Oct 2026, 27 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Nov 2027 → Oct 2026 and completion Nov 2028 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2024
First posted
Jan 19, 2024
StartActual
Jun 20, 2024
Primary completionActual
Oct 7, 2026was Nov 2027
CompletionActual
Oct 7, 2026was Nov 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Terminated→Withdrawn Funding unavailable
changed Oct 9, 2026 · changed Oct 16, 2026
Primary completion
Nov 30, 2027→Oct 7, 2026 (actual)
Oct 9, 2026
Study completion
Nov 1, 2028→Oct 7, 2026 (actual)
Oct 9, 2026
Enrollment
43 (estimated)→0
Oct 16, 2026
Show all 2 updates
  1. Oct 16, 2026
    Terminated→Withdrawn
    Why stopped Funding unavailable
    Enrollment 1→0
  2. Oct 9, 2026
    Suspended→Terminated
    Primary completion Nov 30, 2027→Oct 7, 2026 (now actual)
    Study completion Nov 1, 2028→Oct 7, 2026 (now actual)
    Enrollment 43 (estimated)→1 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06213298
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Jun 20, 2024
Primary completion
Oct 7, 2026
Completion
Oct 7, 2026
Last update
Oct 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Piper methysticum root

Start the discussion